260 related articles for article (PubMed ID: 30323112)
1. Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease.
Pirola CJ; Garaycoechea M; Flichman D; Arrese M; San Martino J; Gazzi C; Castaño GO; Sookoian S
J Lipid Res; 2019 Jan; 60(1):176-185. PubMed ID: 30323112
[TBL] [Abstract][Full Text] [Related]
2. The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease.
Sun DQ; Wang TY; Zheng KI; Zhang HY; Wang XD; Targher G; Byrne CD; Chen YP; Yuan WJ; Jin Y; Zheng MH
Nutr Metab Cardiovasc Dis; 2021 Jun; 31(6):1822-1831. PubMed ID: 33853719
[TBL] [Abstract][Full Text] [Related]
3. The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD.
Vilar-Gomez E; Pirola CJ; Sookoian S; Wilson LA; Liang T; Chalasani N
Clin Transl Gastroenterol; 2021 Sep; 12(9):e00400. PubMed ID: 34506332
[TBL] [Abstract][Full Text] [Related]
4. 17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease.
Ma Y; Belyaeva OV; Brown PM; Fujita K; Valles K; Karki S; de Boer YS; Koh C; Chen Y; Du X; Handelman SK; Chen V; Speliotes EK; Nestlerode C; Thomas E; Kleiner DE; Zmuda JM; Sanyal AJ; ; Kedishvili NY; Liang TJ; Rotman Y
Hepatology; 2019 Apr; 69(4):1504-1519. PubMed ID: 30415504
[TBL] [Abstract][Full Text] [Related]
5. Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort.
Ting YW; Kong AS; Zain SM; Chan WK; Tan HL; Mohamed Z; Pung YF; Mohamed R
Clin Mol Hepatol; 2021 Jul; 27(3):486-498. PubMed ID: 33618508
[TBL] [Abstract][Full Text] [Related]
6. HSD17B13 rs72613567 protects against liver diseases and histological progression of nonalcoholic fatty liver disease: a systematic review and meta-analysis.
Wang P; Wu CX; Li Y; Shen N
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8997-9007. PubMed ID: 32964989
[TBL] [Abstract][Full Text] [Related]
7. A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease.
Yang J; Trépo E; Nahon P; Cao Q; Moreno C; Letouzé E; Imbeaud S; Bayard Q; Gustot T; Deviere J; Bioulac-Sage P; Calderaro J; Ganne-Carrié N; Laurent A; Blanc JF; Guyot E; Sutton A; Ziol M; Zucman-Rossi J; Nault JC
Hepatology; 2019 Jul; 70(1):231-240. PubMed ID: 30908678
[TBL] [Abstract][Full Text] [Related]
8. Association of HSD17B13 rs72613567:TA with non-alcoholic fatty liver disease in Hispanics/Latinos.
Kallwitz E; Tayo BO; Kuniholm MH; Daviglus M; Zeng D; Isasi CR; Cotler SJ
Liver Int; 2020 Apr; 40(4):889-893. PubMed ID: 31965669
[TBL] [Abstract][Full Text] [Related]
9. Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis.
Tang S; Zhang J; Mei TT; Zhang WY; Zheng SJ; Yu HB
BMC Gastroenterol; 2021 Dec; 21(1):490. PubMed ID: 34930143
[TBL] [Abstract][Full Text] [Related]
10. The rs72613567: TA Variant in the Hydroxysteroid 17-beta Dehydrogenase 13 Gene Reduces Liver Damage in Obese Children.
Di Sessa A; Umano GR; Cirillo G; Marzuillo P; Arienzo MR; Pedullà M; Miraglia Del Giudice E
J Pediatr Gastroenterol Nutr; 2020 Mar; 70(3):371-374. PubMed ID: 31789772
[TBL] [Abstract][Full Text] [Related]
11. A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease.
Abul-Husn NS; Cheng X; Li AH; Xin Y; Schurmann C; Stevis P; Liu Y; Kozlitina J; Stender S; Wood GC; Stepanchick AN; Still MD; McCarthy S; O'Dushlaine C; Packer JS; Balasubramanian S; Gosalia N; Esopi D; Kim SY; Mukherjee S; Lopez AE; Fuller ED; Penn J; Chu X; Luo JZ; Mirshahi UL; Carey DJ; Still CD; Feldman MD; Small A; Damrauer SM; Rader DJ; Zambrowicz B; Olson W; Murphy AJ; Borecki IB; Shuldiner AR; Reid JG; Overton JD; Yancopoulos GD; Hobbs HH; Cohen JC; Gottesman O; Teslovich TM; Baras A; Mirshahi T; Gromada J; Dewey FE
N Engl J Med; 2018 Mar; 378(12):1096-1106. PubMed ID: 29562163
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of
Luukkonen PK; Sakuma I; Gaspar RC; Mooring M; Nasiri A; Kahn M; Zhang XM; Zhang D; Sammalkorpi H; Penttilä AK; Orho-Melander M; Arola J; Juuti A; Zhang X; Yimlamai D; Yki-Järvinen H; Petersen KF; Shulman GI
Proc Natl Acad Sci U S A; 2023 Jan; 120(4):e2217543120. PubMed ID: 36669104
[TBL] [Abstract][Full Text] [Related]
13.
Kalinowski P; Smyk W; Nowosad M; Paluszkiewicz R; Michałowski Ł; Ziarkiewicz-Wróblewska B; Weber SN; Milkiewicz P; Lammert F; Zieniewicz K; Krawczyk M
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555467
[TBL] [Abstract][Full Text] [Related]
14. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity.
Sookoian S; Castaño GO; Scian R; Mallardi P; Fernández Gianotti T; Burgueño AL; San Martino J; Pirola CJ
Hepatology; 2015 Feb; 61(2):515-25. PubMed ID: 25302781
[TBL] [Abstract][Full Text] [Related]
15. Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension.
Scheiner B; Stättermayer AF; Schwabl P; Bucsics T; Paternostro R; Bauer D; Simbrunner B; Schmidt R; Marculescu R; Ferlitsch A; Peck-Radosavljevic M; Pinter M; Trauner M; Reiberger T; Ferenci P; Mandorfer M
Liver Int; 2020 Feb; 40(2):393-404. PubMed ID: 31967400
[TBL] [Abstract][Full Text] [Related]
16. TA allele of rs2070673 in the CYP2E1 gene is associated with lobular inflammation and nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic fatty liver disease.
Ma HL; Chen SD; Zheng KI; Yu Y; Wang XX; Tang LJ; Li G; Rios RS; Huang OY; Zheng XY; Xu RA; Targher G; Byrne CD; Wang XD; Chen YP; Zheng MH
J Gastroenterol Hepatol; 2021 Oct; 36(10):2925-2934. PubMed ID: 34031913
[TBL] [Abstract][Full Text] [Related]
17. Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease.
Luukkonen PK; Tukiainen T; Juuti A; Sammalkorpi H; Haridas PAN; Niemelä O; Arola J; Orho-Melander M; Hakkarainen A; Kovanen PT; Dwivedi O; Groop L; Hodson L; Gastaldelli A; Hyötyläinen T; Orešič M; Yki-Järvinen H
JCI Insight; 2020 Mar; 5(5):. PubMed ID: 32161197
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of 17β-hydroxysteroid dehydrogenase 13 at serine 33 attenuates nonalcoholic fatty liver disease in mice.
Su W; Wu S; Yang Y; Guo Y; Zhang H; Su J; Chen L; Mao Z; Lan R; Cao R; Wang C; Xu H; Zhang C; Li S; Gao M; Chen X; Zheng Z; Wang B; Liu Y; Liu Z; Wang Z; Liu B; Fan X; Zhang X; Guan Y
Nat Commun; 2022 Nov; 13(1):6577. PubMed ID: 36323699
[TBL] [Abstract][Full Text] [Related]
19. Impact of a Loss-of-Function Variant in
Gil-Gómez A; Rojas Á; García-Lozano MR; Muñoz-Hernández R; Gallego-Durán R; Maya-Miles D; Montero-Vallejo R; Gato S; Gallego J; Francés R; Soriano G; Ampuero J; Romero-Gómez M
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233142
[TBL] [Abstract][Full Text] [Related]
20. Individualized Polygenic Risk Score Identifies NASH in the Eastern Asia Region: A Derivation and Validation Study.
Gao F; Zheng KI; Chen SD; Lee DH; Wu XX; Wang XD; Targher G; Byrne CD; Chen YP; Kim W; Zheng MH
Clin Transl Gastroenterol; 2021 Mar; 12(3):e00321. PubMed ID: 33704100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
